Spero Therapeutics, Inc. recently announced the approval of 116,667 restricted stock unit awards to a new employee as an inducement under the 2019 Inducement Equity Incentive Plan. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) and reflects the company’s focus on identifying and developing novel treatments for rare diseases and multi-drug resistant bacterial infections.
Additionally, Spero Therapeutics saw a significant improvement in its financial performance, with a surge in cash and cash equivalents by 85.99% in the third quarter of 2023 compared to the previous year. Despite an increase in current liabilities affecting the Quick Ratio, the trailing twelve months Quick Ratio rose to 4.31, exceeding the company’s average.
These developments highlight Spero Therapeutics’ commitment to growth and innovation in the biopharmaceutical industry.
Comments